Navigation Links
Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
Date:11/4/2008

CALGARY, Nov. 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has made a decision to pursue a pivotal (Phase II/III) randomized trial using the combination of REOLYSIN(R) with paclitaxel/carboplatin in refractory patients with head and neck cancers. The decision was made following a review of results by the Company's Board of Directors from the Company's ongoing U.K. Phase I and Phase II combination REOLYSIN(R) and paclitaxel/carboplatin clinical trials. The results were presented November 1, 2008 at the International Society for Biological Therapy of Cancer (iSBTc) annual meeting in San Diego, CA.

"Eight out of nine head and neck patients reported on to date from the Phase I and Phase II studies had either a partial response or stabilization of disease," said Dr. Brad Thompson, President and CEO of Oncolytics, "This response rate exceeds that of the current standard of care for this patient group, and more than warrants proceeding to a pivotal program."

Oncolytics is currently convening a group of experts in Europe and the U.S. to design a protocol for the Phase II/III trial, which will then be submitted to the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMEA) for review. Following FDA and EMEA review, Oncolytics expects to file for approval for this trial early in 2009.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-look
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Clinical Update Conference Call
2. Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
3. Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
4. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
5. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
6. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
7. Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
8. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
9. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
10. Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale
11. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
(Date:1/14/2014)... 2014  3D Communications, a leading provider of strategic communications services to ... events in the United States and ... Cox , JD, is returning to the firm,s Washington, ... 3D after more than two years of service as Associate Commissioner ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... England, February 14 Executives from Senexis,and O2H, ... under which,O2H will provide synthetic and computational chemistry ... an FTE basis., "We believe our collaboration ... and will benefit our search for new,therapeutics to ...
... Feb. 14 AspenBio Pharma,Inc. (Nasdaq: APPY ) ... drugs and diagnostics for animals and humans, has been,invited ... Growth Stock,Conference. The conference will be held February 18-21, ... California., Roth Capital Partners Stock Conferences are one ...
... Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that ... quarter and full year 2007,financial results and provide a ... Eastern Time (2:00 p.m. Pacific Time). Financial results,for the ... be released,earlier that day., Interested parties may access ...
Cached Biology Technology:Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration 2AspenBio Pharma to Present at the Roth Capital Partners 20th Annual Growth Stock Conference 2Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast 2
(Date:4/23/2014)... is a technique used to read quickly. It ... skipping non-essential words and/ or sentences. Similarly to ... to quickly "read" genetic information. Genes that need ... the smaller the encoding message, the easier it ... from Instituto Gulbenkian de Cincia (IGC, Portugal) and ...
(Date:4/22/2014)... 2014) -- There are all sorts of signaling strategies ... their colorful tails; satin bowbirds build specialized stick structures, ... objects; and European bitterling males show off bright nuptial ... unique method to communicate with others. , ... can have profound fitness implications for individuals that are ...
(Date:4/22/2014)... 22, 2014) Biotechnology scientists must be aware of ... and licensing guidelines, according to a new paper from ... in the current issue of the journal Regenerative ... 2013 U.S. Supreme Court ruling in the case Association ... occurring genes are unpatentable. The court case and rulings ...
Breaking Biology News(10 mins):Cell division speed influences gene architecture 2Best practices in communication for the animal world 2Best practices in communication for the animal world 3New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3
... 2013 Medbox, Inc. (OTC Markets: MDBX) ( www.medboxinc.com ), ... the medical and retail industries, announced that their patented software ... means to meet the priorities spelled out by the US ... United States Attorneys titled, "Guidance Regarding Marijuana ...
... flatworms have the remarkable ability to regrow any missing body ... the molecular basis of regeneration. Over the ... differ depending on the severity of the injury they suffer. ... wound reacts at the cellular and molecular levels quite differently ...
... to the origin of species as "that mystery of mysteries," ... cannot fully explain how new animals and plants arise. ... based on the assumption that the main cause of the ... formation of barriers to reproduction between populations. Those barriers ...
Cached Biology News:Medbox's Marijuana Dispensing System Assists Operators in Complying with Federal Government's New Canna-Business Guidelines 2Medbox's Marijuana Dispensing System Assists Operators in Complying with Federal Government's New Canna-Business Guidelines 3Tissue loss triggers regeneration in planarian flatworms 2Long-held assumption about emergence of new species questioned 2Long-held assumption about emergence of new species questioned 3
Vented Caps for 75 cm2 Flasks...
BD BioCoat Poly-D-Lysine 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine....
BD BioCoat Laminin 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
... Ciphergens ProteinChip System, Series 4000 incorporates ... clinical researchers and biologists in biomarker research. ... the fastest route for converting biomarker discoveries ... platform. The Series 4000 is designed to ...
Biology Products: